PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Carboard box 10 x 24 g syringes

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Panacur Equine 187.5 mg/g Oral Paste

2. STATEMENT OF ACTIVE SUBSTANCES

Each 24 g syringe contains 4.5 g fenbendazole.

3. PACKAGE SIZE

10 x 24 g

4. TARGET SPECIES

Horses and other equines.

5. INDICATIONS

Horse wormer.

6. ROUTES OF ADMINISTRATION

Oral use.

The veterinary medicinal product should be administered orally by squeezing the paste from the syringe onto the back of the tongue. No dietary control is required before or after treatment.

7 WITHDRAWAL PERIODS

Withdrawal periods:
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.
Keep the syringe in the outer carton.
Protect from direct sunlight.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Marketing Authorisation Holder:
Intervet International B.V.

14. MARKETING AUTHORISATION NUMBERS

Vm 06376/4094

15. BATCH NUMBER

Lot {number}

Class of anthelmintic:

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Cardboard box/ 24 g syringes

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Panacur Equine 187.5 mg/g Oral Paste

2. STATEMENT OF ACTIVE SUBSTANCES

Each 24 g syringe contains 4.5 g fenbendazole.
This veterinary medicinal product is a ready-to-administer, oral paste for horses and other equines.

3. PACKAGE SIZE

24 g

4. TARGET SPECIES

Horses and other equines.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.
This veterinary medicinal product should be administered orally by squeezing the paste from the syringe onto the back of the tongue. No dietary control is required before or after treatment.

7 WITHDRAWAL PERIODS

Withdrawal periods:
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.
Keep the syringe in the outer carton.
Protect from direct sunlight.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

14. MARKETING AUTHORISATION NUMBERS

Vm 06376/4094

15. BATCH NUMBER

Lot {number}

Class of anthelmintic:

1-BZ

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Label/syringe

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Panacur Equine 187.5 mg/g Oral Paste



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each 24 g syringe contains 4.5 g fenbendazole.

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Panacur Equine 187.5 mg/g Oral Paste

2. Composition

Each gram of paste contains:

Active substance:

Fenbendazole	187.5 mg

Excipients:

Methyl parahydroxybenzoate	1.7 mg
Propyl parahydroxybenzoate	0.16 mg

A white to light grey homogenous oral paste.

3. Target species

Horses and other equines.

4. Indications for use

A broad spectrum anthelmintic for the treatment and control of adult and immature roundworms of the gastrointestinal tract in horses and other equines. This veterinary medicinal product has an ovicidal effect on nematode eggs.

This veterinary medicinal product effectively treats and controls the following roundworm infections:
Large strongyles (adults and migrating larval stages of *S. vulgaris*; adults and tissue larval stages of *S. edentatus*).
Benzimidazole susceptible adult and immature small strongyles (cyathostomes), including encysted mucosal 3rd and 4th stage larvae; it is also effective against encysted inhibited 3rd stage larvae in the mucosa.
Adult and immature *Oxyuris* spp., *Strongyloides* spp. and *Parascaris equorum*.

5. Contraindications

None known.

6. Special warnings

Special warnings:
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Under dosing, which may be due to underestimation of bodyweight, misadministration of the veterinary medicinal product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Resistance to fenbendazole has been reported in cyathostomes in horses. Therefore, the use of this veterinary medicinal product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

Special precautions for safe use in the target species:
Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Direct contact with the skin should be kept to a minimum.
Personal protective equipment consisting of impermeable rubber gloves should be worn when handling the veterinary medicinal product. Wash hands after use.

Pregnancy:
Pregnant mares and foals may be safely treated with fenbendazole at therapeutic dosage levels.

Interaction with other medicinal products and other forms of interaction:
None known.

Overdose:
Benzimidazoles have a high margin of safety.

Major incompatibilities:
None known.

7. Adverse events

Horses and other equines:
None known.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine
e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

The veterinary medicinal product should be administered orally by squeezing the paste from the syringe onto the back of the tongue.
No dietary control is required before or after treatment.

Routine treatment:
Administer orally, 1 syringe per 600 kg bodyweight.
(= 7.5 mg fenbendazole/kg bodyweight)

Practical dosage recommendations:

Up to 100 kg	Miniature ponies	Syringe mark 100 kg
101 to 300 kg	Donkey, Shetland and other small ponies & foals	Syringe mark 300 kg (½ syringe)
301 to 400 kg	Dartmoor, New Forest, Welsh	Syringe mark 400 kg
401 to 500 kg	Light hunters, Arabs, etc.	Syringe mark 500 kg
501 to 600 kg	Thoroughbreds	Syringe mark 600 kg (1 syringe)
601 kg and over	Heavy hunters, draught horses	1 full syringe plus additional 100 kg syringe marks for each extra 100 kg bodyweight

Increased dosing for specific infections:
Five-day course:
For the treatment and control of migrating and tissue larval stages of large strongyles, encysted mucosal 3rd and 4th stage small strongyle larvae and encysted inhibited 3rd stage small strongyle larvae in the mucosa, administer 1 syringe per 600 kg bodyweight daily for 5 days.
(= 7.5 mg fenbendazole/kg bodyweight daily for 5 days)

Single dose treatments:
For the treatment and control of encysted mucosal stages of small strongyles administer 1 syringe per 150 kg bodyweight.
(= 30 mg fenbendazole/kg bodyweight)

For the treatment and control of migrating stages of large strongyles administer 1 syringe per 75 kg bodyweight.
(= 60 mg fenbendazole/kg bodyweight)

For the treatment and control of *Strongyloides westeri* in sucking foals administer 1 syringe per 90 kg bodyweight.
(= 50 mg fenbendazole/kg bodyweight)

Recommended dosing programme
Inappropriate use of anthelmintics may increase resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on professional advice and take into account current best practice recommendations for parasite control.

9. Advice on correct administration

To ensure a correct dosage, bodyweight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended. Accuracy of the dosing device should be checked.

10. Withdrawal periods

Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 25 °C.
Protect from direct sunlight.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

This veterinary medicinal product should not enter water courses as fenbendazole may be dangerous for fish and other aquatic organisms. Do not contaminate ponds, waterways or ditches with the veterinary medicinal product or used container.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 06376/4094

Pack sizes:
Cardboard box with 1 or 10 syringes of 24 g syringes.
Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

16. Contact details

Marketing authorisation holder:
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Netherlands

Manufacturer responsible for batch release:
Intervet Productions S.A.
Rue de Lyon
27460 Igoville
France

Local representative:
MSD Animal Health UK Limited
Walton Manor, Walton
Milton Keynes
MK7 7AJ, United Kingdom

Contact details to report suspected adverse reactions:
UK(GB)
MSD Animal Health UK Ltd.
Tel.: +44 (0)1908 685685

UK(NI)
Intervet Ireland Ltd.
Tel.: +353 (0)1 2970220

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-VPS

Environmental properties
Fenbendazole is toxic to fish and other aquatic organisms.

Class of anthelmintic:

1-B

Gavin Hall

Approved: 16 April 2026